OzempSick

About this video

Under Gillett’s coined label for GLP-1 side effects, this episode examines reports linking semaglutide and related drugs to depression, anxiety and suicidal thinking. The hosts review published case reports where symptoms began after starting treatment and eased after stopping, and larger observational data they say show a pattern rising with drug potency. They also stress confounders: pivotal trials excluded people with psychiatric histories, severe calorie restriction and rapid weight loss can themselves depress mood, food may have been a coping tool, and access or cost disruptions can cause distress. A dopamine-related mechanism is discussed as hypothesis, not proof. Their practical message is screening, slower loss and monitoring.

Key takeaways

• Post-marketing reports are how new psychiatric signals surface, and should be reported
• Trial populations that excluded psychiatric history limit what trials can rule out
• Rapid energy restriction alone can mimic or unmask depression, the hosts argue
• Potency and speed of weight loss are presented as reasons for closer monitoring
• A prior mental-health history calls for an explicit monitoring plan before starting

Episode details: published November 12, 2024 · 1.4K views · 26:33 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.

← Previous: Reacting To “Peptides For Dummies” | The Gillett Health Podcast #88 · Next: Peptides & Hormones →

All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)